Pfizer is a great option for both dividend and growth investors. Summit Therapeutics is a rising biotech stock with more room to run. Vertex Pharmaceuticals is a great stock to buy on the dip. David ...

FDA approved tafasitamab with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, based on clinical trial results. Troy Anderson's experience with Monjuvi showed significant ...

The Chargers waived Vidal on Tuesday. The 2024 sixth-rounder entered training camp in the mix for a depth role behind Najee Harris (eye) and rookie Omarion Hampton. Vidal wasn't the most efficient ...

PDS0101 and pembrolizumab combination achieved a median overall survival of 39.3 months in HPV16-positive head and neck cancer patients with a CPS of at least 1. The VERSATILE-002 trial showed ...

The advancement of Pfizer’s antibody-drug conjugate portfolio has not spared the former Seagen site—and those who helped develop the therapies—from layoffs. Pfizer is laying off 100 employees in ...

PDS Biotech has reported final phase 2 data on PDS0101 in the tough-to-treat head and neck cancer setting, linking a combination of the immunotherapy and Keytruda to median overall survival (OS) of 39 ...

After many U.S. biopharma companies posted sales declines in the first quarter, the domestic pharma industry largely bounced back to growth in the second quarter. In this episode of "The Top Line," ...

The FDA’s recent rebuff of Replimune’s melanoma candidate has rippled across the industry, prompting one biotech to shutter a clinical trial evaluating a similar drug. Krystal Biotech has discontinued ...

A recent study reveals that 89% of patients with unresectable desmoplastic melanoma respond to Keytruda. Nearly nine out of 10 patients with a rare and aggressive form of skin cancer that couldn’t be ...

The United States may be losing its edge in mRNA technology­­. The technology, which powered life-saving COVID-19 vaccines and is now rocketing new cancer therapeutics forward, will soon undergo a ...

The platform strategy of using one molecule to target an underlying biological pathway to address many different diseases can be a goldmine for smaller companies. But it also has a unique set of ...